CRO Services
Up Close and Personal with Dr. Denise Milovan
Neuroscientist Dr.
Five Ways Altasciences Simplifies the Drug Development Process for You
Bringing new drugs to market, from lead candidate selection through preclinical testing, to clinical proof of concept, is a complex, time-consuming, and costly process.
Making Early-Phase Drug Development Faster, Better, and More Efficient
Early-phase drug discovery and drug development are complex processes, where many moving parts can, and do, influence the success of a program.
Data Management Excellence – What it Takes
What Data Managers Do
Gathering, analyzing, and presenting the data to support life-altering new medicines for people around the world is a long, complex, and detailed proces
2020 Year in Review
2020 has been quite a year! Each year, we strive to provide you with a more innovative, simplified, and seamless early phase drug development journey. And the past 12 months have been no exception.
Study Site Management: Eight Reasons to Choose Altasciences
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
An important consideration in choosing a research partner for your drug development programs is their experience and expertise in managing their study sites. Making the Most of your CRO Partnership
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
PartnershipChoosing the right CRO as a partner for your drug development programs is a vitally important step to achieving critical decision making The FDA Animal Rule and Standard for Exchange of Nonclinical Data (SEND)
|